Cargando…
Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
Finding a vaccine that can last a long time and effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today. The various vaccines that have been available have decreased in effectiveness and require booster administration. As the professional antigen presenting c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485669/ https://www.ncbi.nlm.nih.gov/pubmed/36148241 http://dx.doi.org/10.3389/fimmu.2022.989685 |
_version_ | 1784792124450930688 |
---|---|
author | Jonny, Jonny Putranto, Terawan Agus Irfon, Raoulian Sitepu, Enda Cindylosa |
author_facet | Jonny, Jonny Putranto, Terawan Agus Irfon, Raoulian Sitepu, Enda Cindylosa |
author_sort | Jonny, Jonny |
collection | PubMed |
description | Finding a vaccine that can last a long time and effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today. The various vaccines that have been available have decreased in effectiveness and require booster administration. As the professional antigen presenting cell, Dendritic Cells can also activate the immune system, especially T cells. This ability makes dendritic cells have been developed as vaccines for some types of diseases. In SARS-CoV-2 infection, T cells play a vital role in eliminating the virus, and their presence can be detected in the long term. Hence, this condition shows that the formation of T cell immunity is essential to prevent and control the course of the disease. The construction of vaccines oriented to induce strong T cells response can be formed by utilizing dendritic cells. In this article, we discuss and illustrate the role of dendritic cells and T cells in the pathogenesis of SARS-CoV-2 infection and summarizing the crucial role of dendritic cells in the formation of T cell immunity. We arrange the basis concept of developing dendritic cells for SARS-CoV-2 vaccines. A dendritic cell-based vaccine for SARS-CoV-2 has the potential to be an effective vaccine that solves existing problems. |
format | Online Article Text |
id | pubmed-9485669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94856692022-09-21 Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic Jonny, Jonny Putranto, Terawan Agus Irfon, Raoulian Sitepu, Enda Cindylosa Front Immunol Immunology Finding a vaccine that can last a long time and effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today. The various vaccines that have been available have decreased in effectiveness and require booster administration. As the professional antigen presenting cell, Dendritic Cells can also activate the immune system, especially T cells. This ability makes dendritic cells have been developed as vaccines for some types of diseases. In SARS-CoV-2 infection, T cells play a vital role in eliminating the virus, and their presence can be detected in the long term. Hence, this condition shows that the formation of T cell immunity is essential to prevent and control the course of the disease. The construction of vaccines oriented to induce strong T cells response can be formed by utilizing dendritic cells. In this article, we discuss and illustrate the role of dendritic cells and T cells in the pathogenesis of SARS-CoV-2 infection and summarizing the crucial role of dendritic cells in the formation of T cell immunity. We arrange the basis concept of developing dendritic cells for SARS-CoV-2 vaccines. A dendritic cell-based vaccine for SARS-CoV-2 has the potential to be an effective vaccine that solves existing problems. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485669/ /pubmed/36148241 http://dx.doi.org/10.3389/fimmu.2022.989685 Text en Copyright © 2022 Jonny, Putranto, Irfon and Sitepu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jonny, Jonny Putranto, Terawan Agus Irfon, Raoulian Sitepu, Enda Cindylosa Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic |
title | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic |
title_full | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic |
title_fullStr | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic |
title_full_unstemmed | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic |
title_short | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic |
title_sort | developing dendritic cell for sars-cov-2 vaccine: breakthrough in the pandemic |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485669/ https://www.ncbi.nlm.nih.gov/pubmed/36148241 http://dx.doi.org/10.3389/fimmu.2022.989685 |
work_keys_str_mv | AT jonnyjonny developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic AT putrantoterawanagus developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic AT irfonraoulian developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic AT sitepuendacindylosa developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic |